- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00671619
Study of ESBA105 Eye Drops in Healthy Subjects
August 22, 2008 updated by: ESBATech AG
A Phase I, Randomized, Vehicle-Controlled, Double-Blind, Mono-Centric, Single and Repeated Dose, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ESBA105 Eye Drops in Healthy Subjects
Objectives:
To evaluate the safety, tolerability and pharmacokinetics of ESBA105 administered topically to the eye for up to 28 days in healthy volunteers.
To determine the systemic exposure to ESBA105 upon single and repeated-dose topical application to the eye in healthy volunteers.
Study Overview
Detailed Description
ESBA105 is an anti TNF single chain antibody fragment
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Basel, Switzerland
- Swiss Pharma Contract
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female Caucasian subjects.
- Written informed consent prior to any study procedures including screening tests for eligibility.
- Subjects should be in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
- Normal sitting blood pressure and pulse rate, i.e.: BP: 100-160 mm Hg systolic, 50-90 mm Hg diastolic and pulse rate: 45-100 bpm. Blood pressure and pulse will be measured after 3 minutes resting in a sitting position.
- Bilateral corrected visual acuity of at least 0.9
- No need for regular concomitant medication.
- Ability to communicate well with the investigator and comply with the requirements of the entire study.
- Use of qualified contraception
Exclusion Criteria:
- Any evidence of infectious disease as evidenced by medical history, clinical examination, positive serology results which indicate the presence of hepatitis B and/ or C or HIV infection or positive results of the QuantiFERON TB Gold test based latent tuberculosis testing.
- History of serious adverse reactions or hypersensitivity to any drug.
- Presence or history of any allergy including allergic conjunctivitis requiring acute or chronic treatment (seasonal allergic rhinitis not associated to conjunctivitis which requires no treatment may be tolerated).
- Abnormal physical findings of clinical significance at the screening examination or baseline which would interfere with the objectives of the study.
- Existence of any surgical or medical condition which might interfere with the evaluation of the general drug safety and tolerability including clinically relevant ophthalmological diseases, impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, haematological abnormalities, psychiatric diseases, chronic symptoms of pronounced constipation or diarrhoea or conditions associated with total or partial obstruction of the urinary tract.
- Shallow anterior chamber, closed angle glaucoma or any other contraindication to eye dilation for ophthalmological examination.
- History or presence of any other clinically relevant (in the opinion of the Investigator) ocular disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
safety and tolerability
Time Frame: several timepoints
|
several timepoints
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2008
Primary Completion (Actual)
July 1, 2008
Study Completion (Actual)
August 1, 2008
Study Registration Dates
First Submitted
April 28, 2008
First Submitted That Met QC Criteria
May 2, 2008
First Posted (Estimate)
May 5, 2008
Study Record Updates
Last Update Posted (Estimate)
August 25, 2008
Last Update Submitted That Met QC Criteria
August 22, 2008
Last Verified
August 1, 2008
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ESBA105CRD01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.